Although 1 μM Gefitinib does not inhibit PI3K activation in HCT116 cells, it inhibits the complexing of K-Ras/PI3K and K-Ras/Raf in NSCLC [92]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.